98%
921
2 minutes
20
Background & Aims: Altered expression of dual specificity phosphatase 1 (DUSP1) is common in tumors including hepatocellular carcinoma (HCC), and is predictive of tumor progression and poor prognosis. However, the tumor suppressive role of DUSP1 has yet to be clearly elucidated.
Methods: The molecular mechanisms of tumor suppression that were investigated were induction of apoptosis, cell cycle inhibition, and regulation of p53. Additionally, the antitumor effect of DUSP1 was assessed using a mouse model. Associated signaling pathways in HCC cells and tissues were examined.
Results: Downregulation of DUSP1 expression was significantly correlated with poor differentiation (p<0.001) and advanced HCC stage (p=0.023). DUSP1 expression resulted in HCC suppression and longer survival (p=0.0002) in a xenoplant mice model. DUSP1 inhibited p38 MAPK phosphorylation and subsequently suppressed HSP27 activation, resulting in enhanced p53 phosphorylation at sites S15, S20, and S46 in HCC cells. Enhanced p53 activation induced the expression of target genes p21 and p27, which are linked to cell cycle arrest and apoptosis. Thus, DUSP1 was potentially linked to p53 activation via the p38 MAPK/HSP27 pathway. Wild-type but not mutant p53 transcriptionally upregulated DUSP1 via its DNA-binding domain. DUSP1 and p53 might collaborate to suppress tumors in hepatocarcinogenesis via a positive regulatory loop.
Conclusions: Our results revealed that disruption of a positive regulatory loop between DUSP1 and p53 promoted HCC development and progression, providing a rationale for a therapeutic agent that restores DUSP1 in HCC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jhep.2014.12.033 | DOI Listing |
Diagn Interv Radiol
September 2025
Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
Purpose: To evaluate the feasibility of abbreviated liver magnetic resonance imaging (AMRI) with a second-shot arterial phase (SSAP) image for the viability of treated hepatocellular carcinoma (HCC) after non-radiation locoregional therapy (LRT).
Methods: We retrospectively enrolled patients with non-radiation LRT for HCC who underwent the modified gadoxetic acid-enhanced liver MRI protocol, which includes routine dynamic and SSAP imaging after the first and second injection of gadoxetic acid, respectively (6 mL and 4 mL, respectively), and an available reference standard for tumor viability in the treated HCC between March 2021 and February 2022. Two radiologists independently reviewed the full-protocol MRI (FP-MRI) and AMRI with SSAP.
J Cancer Res Clin Oncol
September 2025
Department of Radiology, Guizhou Provincial People's Hospital, No. 83 East Zhongshan Road, Guiyang, 550002, Guizhou, China.
Purpose: Targeted therapy with lenvatinib is a preferred option for advanced hepatocellular carcinoma, however, predicting its efficacy remains challenging. This study aimed to build a nomogram integrating clinicoradiological indicators and radiomics features to predict the response to lenvatinib in patients with hepatocellular carcinoma.
Methods: This study included 211 patients with hepatocellular carcinoma from two centers, who were allocated into the training (107 patients), internal test (46 patients) and external test set(58 patients).
Intern Med
September 2025
Department of Gastroenterology and Hepatology, Toyota Kosei Hospital, Japan.
Agranulocytosis is an extremely rare but potentially fatal immune-related adverse event (irAE) induced by immune checkpoint inhibitors (ICIs). Its management, particularly following combination therapies such as durvalumab/tremelimumab (Dur/Tre) for hepatocellular carcinoma (HCC), is challenging owing to limited data. We herein report a 79-year-old man with HCC who developed severe Dur/Tre-induced agranulocytosis that was refractory to granulocyte colony-stimulating factor, high-dose corticosteroids, and intravenous immunoglobulin.
View Article and Find Full Text PDFNihon Shokakibyo Gakkai Zasshi
January 2025
Department of Surgery, Graduate School of Medicine, Kyoto University.
Gut
September 2025
Curtin Medical School, Curtin University, Bentley, Western Australia, Australia